Systematic Evaluation of Voriconazole Pharmacokinetic Models without Pharmacogenetic Information for Bayesian Forecasting in Critically Ill Patients

Voriconazole (VRC) is used as first line antifungal agent against invasive aspergillosis. Model-based approaches might optimize VRC therapy. This study aimed to investigate the predictive performance of pharmacokinetic models of VRC without pharmacogenetic information for their suitability for model...

Descripción completa

Detalles Bibliográficos
Autores principales: Kallee, Simon, Scharf, Christina, Schatz, Lea Marie, Paal, Michael, Vogeser, Michael, Irlbeck, Michael, Zander, Johannes, Zoller, Michael, Liebchen, Uwe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9505877/
https://www.ncbi.nlm.nih.gov/pubmed/36145667
http://dx.doi.org/10.3390/pharmaceutics14091920

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9505877/
https://www.ncbi.nlm.nih.gov/pubmed/36145667
http://dx.doi.org/10.3390/pharmaceutics14091920

Ejemplares similares